HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has scheduled a conference call to discuss its financial results for the third quarter ended September 30, 2026. The call will take place on Thursday, November 12, 2026, at 4:30 p.m. ET, according to a press release issued by HeartBeam (NASDAQ: BEAT). A press release detailing the quarterly results will be issued before the call.
Management will also provide updates on recent achievements, including results from the ALIGN-ACS pilot study, and upcoming milestones for the company’s Heart Attack Detection program. The call will be hosted by Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank, and will be followed by a question-and-answer session.
Participants can access the conference by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, with a telephone replay accessible approximately three hours after the call through November 26, 2026. To view the full press release, visit https://ibn.fm/QEwx4.
HeartBeam is dedicated to transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. For details on the intended use of its technology, refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications.
The quarterly update comes as HeartBeam advances its Heart Attack Detection program and prepares to share results from the ALIGN-ACS pilot study, which could provide further validation of its 3D ECG platform. The conference call offers investors and stakeholders an opportunity to assess the company’s financial health and strategic progress. The announcement was distributed through MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For more information, visit www.MissionIR.com.
